RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07645326 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Interventions

DRUG: Androgen Deprivation Therapy (ADT)
DRUG: Androgen Receptor Pathway Inhibitor (ARPI)
RADIATION: Prostate Radiation
DRUG: Docetaxel

Sponsor

Georgetown University

Collaborators

[object Object]